Ozkerim, U.; Isik, D.; Kinikoglu, O.; Oksuz, S.; Altintas, Y.E.; Akdag, G.; Yildirim, S.; Basoglu, T.; Surmeli, H.; Odabas, H.;
et al. Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study. J. Pers. Med. 2026, 16, 8.
https://doi.org/10.3390/jpm16010008
AMA Style
Ozkerim U, Isik D, Kinikoglu O, Oksuz S, Altintas YE, Akdag G, Yildirim S, Basoglu T, Surmeli H, Odabas H,
et al. Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study. Journal of Personalized Medicine. 2026; 16(1):8.
https://doi.org/10.3390/jpm16010008
Chicago/Turabian Style
Ozkerim, Ugur, Deniz Isik, Oguzcan Kinikoglu, Sila Oksuz, Yunus Emre Altintas, Goncagul Akdag, Sedat Yildirim, Tugba Basoglu, Heves Surmeli, Hatice Odabas,
and et al. 2026. "Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study" Journal of Personalized Medicine 16, no. 1: 8.
https://doi.org/10.3390/jpm16010008
APA Style
Ozkerim, U., Isik, D., Kinikoglu, O., Oksuz, S., Altintas, Y. E., Akdag, G., Yildirim, S., Basoglu, T., Surmeli, H., Odabas, H., & Turan, N.
(2026). Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study. Journal of Personalized Medicine, 16(1), 8.
https://doi.org/10.3390/jpm16010008
